AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7261830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol 25 mg 4 times a day
Number of subjects: 55
Study 7261830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol combined with head of bed elevation
Number of subjects: 55
Study 7261830 — intervention group
Group type: COMPARATOR
Intervention: Antacid foam tablets
Number of subjects: 55
Study 30528313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-respiratory fitness (CRF) assessed with peak oxygen uptake during maximum exercise
Number of subjects: 80
Study 28959438 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker-led education intervention
Number of subjects: 1934
Study 28959438 — intervention group
Group type: COMPARATOR
Intervention: Comparison clusters (control)
Number of subjects: 1934
Study 24089377 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (140 ml/day, containing 8 mmol of NO3(‐))
Number of subjects: 9
Study 24089377 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation
Number of subjects: 9
Study 21868736 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 108
Study 21868736 — intervention group
Group type: COMPARATOR
Intervention: Problem-solving therapy
Number of subjects: 108
Study 21868736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 19485290 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium:sapphire laser trabeculoplasty (TLT)
Number of subjects: 37
Study 19485290 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 37
Study 17915638 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicidum tablet preparation 1 (75 mg, 3 tablets)
Number of subjects: 20
Study 17915638 — intervention group
Group type: COMPARATOR
Intervention: Helicidum tablet preparation 2 (75 mg, 3 tablets)
Number of subjects: 20
Study 15819302 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided bare metal stent implantation (BMS)
Number of subjects: 103
Study 11570966 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH-primed group (150 iu recombinant FSH day(-1) for 3 days)
Number of subjects: 28
Study 11570966 — intervention group
Group type: COMPARATOR
Intervention: Non-primed group (no stimulation)
Number of subjects: 28
Study 11570966 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH-primed group
Number of subjects: 28
Study 9436937 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-Dex (oral idarubicin and dexamethasone)
Number of subjects: 30
Study 9436937 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAP (cis-platin, Ara-C and dexamethasone)
Number of subjects: 30
Study 9436937 — intervention group
Group type: COMPARATOR
Intervention: LD cyclophosphamide
Number of subjects: 30
Study 9436937 — intervention group
Group type: COMPARATOR
Intervention: HD cyclophosphamide
Number of subjects: 30
Study 9436937 — intervention group
Group type: COMPARATOR
Intervention: cis-platin/VP16
Number of subjects: 30
Study 9436937 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAP
Number of subjects: 30
Study 8513039 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 2
Study 8513039 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 2
Study 3106450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn 20 mg
Number of subjects: 5
Study 3106450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn 40 mg
Number of subjects: 5
Study 3106450 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study 30075546 — intervention group
Group type: COMPARATOR
Intervention: anti-plasminogen binding peptide (a-PBP)
Number of subjects: 29
Study 30075546 — intervention group
Group type: COMPARATOR
Intervention: immunoglobulin G4 (IgG4)
Number of subjects: 29
Study 30075546 — intervention group
Group type: COMPARATOR
Intervention: IgG4
Number of subjects: 29
Study 30075546 — intervention group
Group type: COMPARATOR
Intervention: c-ANCA
Number of subjects: 29
Study 27581578 — intervention group
Group type: COMPARATOR
Intervention: Food secure households
Number of subjects: 14600
Study 27581578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild HFI
Number of subjects: 14600
Study 27581578 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate HFI
Number of subjects: 14600
Study 27581578 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe HFI
Number of subjects: 14600
Study 25204507 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 μg/kg of dexmedetomidine (low-dose group)
Number of subjects: 138
Study 25204507 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg of dexmedetomidine (subclinical dose group)
Number of subjects: 138
Study 25204507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg of dexmedetomidine (clinical dose group)
Number of subjects: 138
Study 25204507 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (saline group)
Number of subjects: 138
Study 25204507 — intervention group
Group type: EXPERIMENTAL
Intervention: All dexmedetomidine doses
Number of subjects: 138
Study 25204507 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 138
Study 22923662 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate 500/125 mg three times a day for 8 days
Number of subjects: 310
Study 22923662 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day for 8 days
Number of subjects: 310
Study 22923662 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 310
Study 22923662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 19957178 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 35
Study 19957178 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 35
Study 18335329 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg on days 3-5
Number of subjects: 22
Study 18335329 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg
Number of subjects: 22
Study 16466009 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic pancreatitis (CP)
Number of subjects: 39
Study 16466009 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic pancreatitis (CP) at Cambridge IV stage
Number of subjects: 39
Study 16466009 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 39
Study 11979494 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition with heuristics (distance-decay and circle hypothesis)
Number of subjects: 21
Study 11979494 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no heuristics)
Number of subjects: 21
Study 11979494 — intervention group
Group type: COMPARATOR
Intervention: Predictions generated by Dragnet (geographic profiling system)
Number of subjects: 21
Study 10876541 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Care Nurse Practitioner (ACNP) role
Number of subjects: 0
Study 7782813 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire administered to patients after decision about participation
Number of subjects: 247
Study 1869847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg every 12 h)
Number of subjects: 8
Study 1869847 — intervention group
Group type: COMPARATOR
Intervention: Control (Quinine treatment)
Number of subjects: 8
Study 6342839 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 3837
Study 6342839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 3837
Study 30796477 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that urinary incontinence is normal for ageing
Number of subjects: 4446
Study 30796477 — intervention group
Group type: COMPARATOR
Intervention: Belief that urinary incontinence is not normal for ageing
Number of subjects: 4446
Study 30036440 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast prophylaxis for 2 weeks before pollen season and throughout the season
Number of subjects: 57
Study 30036440 — intervention group
Group type: COMPARATOR
Intervention: Montelukast during pollen season only (control group)
Number of subjects: 57
Study 30036440 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast prophylaxis
Number of subjects: 57
Study 27151024 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO) at a dose of 300 U/(kg·d) for a maximum of 14 days
Number of subjects: 96
Study 27151024 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO)
Number of subjects: 96
Study 27151024 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid (standard dose) for 28 days
Number of subjects: 96
Study 24224779 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency ablation (RFA)
Number of subjects: 120
Study 24224779 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy
Number of subjects: 120
Study 24224779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RFA and Hepatectomy
Number of subjects: 120
Study 23027921 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mmol KHCO(3)/d
Number of subjects: 8
Study 23027921 — intervention group
Group type: COMPARATOR
Intervention: High NaCl intake
Number of subjects: 8
Study 19430043 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0
Study 19430043 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 19430043 — intervention group
Group type: COMPARATOR
Intervention: Indapamide and Perindopril
Number of subjects: 0
Study 17721372 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal coadministered with DTPaHibIPV, oral polio vaccine, and measles‐mumps‐rubella vaccine (group A)
Number of subjects: 322
Study 17721372 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal given alone (group B)
Number of subjects: 322
Study 17721372 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix Junior coadministered with DTPaHibIPV, oral polio vaccine, and measles‐mumps‐rubella vaccine (group C)
Number of subjects: 322
Study 17721372 — intervention group
Group type: COMPARATOR
Intervention: Booster dose for all groups
Number of subjects: 322
Study 15456470 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 0
Study 15456470 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 0
Study 15456470 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 0
Study 12362006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric-oxygen treatment
Number of subjects: 152
Study 12362006 — intervention group
Group type: COMPARATOR
Intervention: Normobaric-oxygen treatment
Number of subjects: 152
Study 9438445 — intervention group
Group type: EXPERIMENTAL
Intervention: 1D MR myocardial tagging in healthy subjects (n=10)
Number of subjects: 17
Study 9438445 — intervention group
Group type: COMPARATOR
Intervention: 1D MR myocardial tagging in patients with chronic pulmonary hypertension (n=7)
Number of subjects: 17
Study 8079605 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth center care (EG)
Number of subjects: 1230
Study 8079605 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care (CG)
Number of subjects: 1230
Study 2480721 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual 4‐hourly morphine dose
Number of subjects: 19
Study 2480721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1102877 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 0
Study 1102877 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 1102877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30942011 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation at Zusanli (ST 36), 30 min every time, once every 8 h, until the end of the first bowel movement.
Number of subjects: 110
Study 30942011 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment only).
Number of subjects: 110
Study 30942011 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation at Zusanli (ST 36).
Number of subjects: 110
Study 28333292 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG on the day of FET and 6 days after FET
Number of subjects: 450
Study 28333292 — intervention group
Group type: COMPARATOR
Intervention: Normal saline on the day of FET and 6 days after FET
Number of subjects: 450
Study 28333292 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU hCG
Number of subjects: 450
Study 28333292 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 450
Study 28333292 — intervention group
Group type: COMPARATOR
Intervention: hCG and normal saline
Number of subjects: 450
Study 28333292 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 450
Study 26156796 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrate enema (100 mmol sodium butyrate/L; 60 mL; n = 7)
Number of subjects: 12
Study 26156796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (140 mmol 0.9% NaCl/L; 60 mL; n = 5)
Number of subjects: 12
Study 22496275 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive medications (statins, antiplatelet therapy, beta-blockers, ACE inhibitors/ARBs)
Number of subjects: 15828
Study 21899544 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM) supplementation (50 mg/kg body weight)
Number of subjects: 18
Study 21899544 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 18
Study 18179672 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema Focused Therapy (SFT)
Number of subjects: 86
Study 18179672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference Focused Psychotherapy (TFP)
Number of subjects: 86
Study 16479521 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation
Number of subjects: 4495
Study 16479521 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin A supplementation
Number of subjects: 4495
Study 16479521 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 vitamin A regimens
Number of subjects: 4495
Study 16479521 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 4495
Study 14685126 — intervention group
Group type: EXPERIMENTAL
Intervention: New classifications for diabetes and healthcare provision strategies
Number of subjects: 0
Study 11070759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 10 mg
Number of subjects: 38
Study 11070759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 38
Study 11070759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg-SR
Number of subjects: 38
Study 11070759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 40 mg-SR
Number of subjects: 38
Study 11070759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg-SR
Number of subjects: 38
Study 11070759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg-SR
Number of subjects: 38
Study 11070759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8629678 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoetharine (5 mg)
Number of subjects: 51
Study 8629678 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (2.5 mg)
Number of subjects: 51
Study 8629678 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoetharine
Number of subjects: 51
Study 1571421 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal ultrasonography during the acute phase of illness
Number of subjects: 25
Study 1571421 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal ultrasonography after antimicrobial therapy
Number of subjects: 25
Study 2865725 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care (SC)
Number of subjects: 10940
Study 2865725 — intervention group
Group type: COMPARATOR
Intervention: Referred-care (RC)
Number of subjects: 10940
Study 31335641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid emotion-focused exposure treatment (n = 58, 10-16 sessions)
Number of subjects: 115
Study 31335641 — intervention group
Group type: COMPARATOR
Intervention: iCBT (n = 57; 8 treatment modules)
Number of subjects: 115
Study 30295222 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresher training session (R (+) group)
Number of subjects: 50
Study 30295222 — intervention group
Group type: COMPARATOR
Intervention: No refresher training session (R (−) group)
Number of subjects: 50
Study 27488944 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (10 mg daily)
Number of subjects: 227
Study 27488944 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg daily)
Number of subjects: 227
Study 27488944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 24569062 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotip mounted Neuropen
Number of subjects: 0
Study 24569062 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic neurological wheel
Number of subjects: 0
Study 24569062 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Neurotip mounted Neuropen and plastic neurological wheel
Number of subjects: 0
Study 22901886 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg mepolizumab
Number of subjects: 621
Study 22901886 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg mepolizumab
Number of subjects: 621
Study 22901886 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg mepolizumab
Number of subjects: 621
Study 22901886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study 20111599 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMVA (1x10^7 pfu)
Number of subjects: 50
Study 20111599 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMVA (5x10^7 pfu)
Number of subjects: 50
Study 20111599 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMVA (2.5x10^8 pfu)
Number of subjects: 50
Study 20111599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18085837 — intervention group
Group type: COMPARATOR
Intervention: IANB plus mock buccal infiltration and mock lingual infiltration
Number of subjects: 0
Study 18085837 — intervention group
Group type: EXPERIMENTAL
Intervention: IANB plus buccal infiltration and mock lingual infiltration
Number of subjects: 0
Study 18085837 — intervention group
Group type: EXPERIMENTAL
Intervention: IANB plus mock buccal infiltration and lingual infiltration
Number of subjects: 0
Study 16260891 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg, three doses at 12-hour intervals, infused continuously over 15 min)
Number of subjects: 44
Study 16260891 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 44
Study 16260891 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg initial dose followed by two doses of 5 mg/kg each after 24 and 48 h, infused continuously over 15 min)
Number of subjects: 44
Study 12226782 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ESWT (low-energy shock wave therapy)
Number of subjects: 32
Study 12226782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (energy-absorbing foil)
Number of subjects: 32
Study 12226782 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ESWT
Number of subjects: 32
Study 12226782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11382863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic REM sleep induction test (CRIT) with 10 mg galanthamine
Number of subjects: 24
Study 11382863 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 24
Study 7589593 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy
Number of subjects: 2
Study 7589593 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 2
Study 2796881 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg of cimetropium bromide 1 hour before bottle
Number of subjects: 40
Study 2796881 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg of cimetropium bromide 1 hour before bottle
Number of subjects: 40
Study 352152 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 500 mg injected intravenously every 12 hours for four doses
Number of subjects: 126
Study 352152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 30192070 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 96
Study 30192070 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation (control group)
Number of subjects: 96
Study 30192070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led counseling
Number of subjects: 96
Study 28874821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval training (SIT)
Number of subjects: 26
Study 28874821 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 26
Study 28874821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SIT and MICT
Number of subjects: 26
Study 25488686 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel (35 mg/m² days 1, 8, 15 every 4 weeks for four or six cycles)
Number of subjects: 299
Study 25488686 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 600 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m², days 1, 8)
Number of subjects: 299
Study 25488686 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel
Number of subjects: 299
Study 25488686 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 299
Study 23352187 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10,000 BVA plus PT
Number of subjects: 68
Study 23352187 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:30,000 BVA plus PT
Number of subjects: 68
Study 23352187 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) injection plus PT
Number of subjects: 68
Study 20919993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic postconditioning (postcon) with three episodes of 30-s inflation and 30-s deflation of the angioplasty balloon
Number of subjects: 0